Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Leukemia ; 29(5): 1051-9, 2015 May.
Article in English | MEDLINE | ID: mdl-25428263

ABSTRACT

As a highly heterogeneous disease, acute myeloid leukemia (AML) needs fine risk stratification to get an optimal outcome of patients. MicroRNAs have florid biological functions and have critical roles in the pathogenesis and prognosis in AML. Expression levels of some single microRNAs are influential for prognosis, but a system integrating several together and considering the weight of each should be more powerful. We thus analyzed the clinical, genetic and microRNA profiling data of 138 de novo AML patients of our institute. By multivariate analysis, we identified that high expression of hsa-miR-9-5p and hsa-miR-155-5p were independent poor prognostic factors, whereas that of hsa-miR-203 had a trend to be a favorable factor. We constructed a scoring system from expression of these three microRNAs by considering the weight of each. The scores correlated with distinct clinical and biological features and outperformed single microRNA expression in prognostication. In both ours and another validation cohort, higher scores were associated with shorter overall survival, independent of other well-known prognostic factors. By analyzing the mRNA expression profiles, we sorted out several cancer-related pathways highly correlated with the microRNA prognostic signature. We conclude that this 3-microRNA scoring system is simple and powerful for risk stratification of de novo AML patients.


Subject(s)
Gene Expression Regulation, Leukemic , Leukemia, Myeloid, Acute/diagnosis , MicroRNAs/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Chromosome Aberrations , Cohort Studies , Cytogenetics , DNA Mutational Analysis , Female , Gene Expression Profiling , Humans , Leukemia, Myeloid, Acute/metabolism , Male , Microarray Analysis , Middle Aged , Multivariate Analysis , Prognosis , Proportional Hazards Models , Real-Time Polymerase Chain Reaction , Regression Analysis , Young Adult
2.
Transplant Proc ; 44(4): 910-2, 2012 May.
Article in English | MEDLINE | ID: mdl-22564582

ABSTRACT

OBJECTIVE: Hepatitis B virus (HBV) infection is hyperendemic in Taiwan. We have reported the outcome of (1) recipients with hepatitis B surface antigen (HBsAg)-positive; HBsAg-negative recipients who receive donor hearts from HBsAg-positive donors; and treatment with lamivudine of hepatitis B flare-ups after heart transplantation, using case numbers that range from 100 to 200. METHODS: From July 1987 to May 2011, all 412 orthotopic heart transplant recipients and donors underwent routine preoperative screening for hepatitis B virus markers and liver function parameters. Lamivudine was prescribed prophylactically for recipients with elevated serum enzyme levels or an HBV DNA virus load before transplantation, or when there was evidence of hepatitis B flare-up after transplantation. Postoperative HBV markers and liver function parameters were collected over a mean follow-up time of 7.8 years. RESULTS: Thirty-four recipients were HBsAg-positive before heart transplantation, and 23 experiencing HBV reactivation upon follow-up requiring lamivudine treatment. Clinical responses were achieved in all of them: 15 were complete and two, slow partial responses. Twenty-six recipients with an HBV naïve status at the time of heart transplantation, and three patients received donor hearts from an HBsAg-positive donor under perioperative hepatitis B immunoglobulin prophylaxis. HBV infection was successfully prevented in two patients, but the other one contracted HBV hepatitis, which was successfully treated with lamivudine. CONCLUSIONS: HBV reactivation after the heart transplantation was common but usually well controlled with lamivudine treatment. Although posttransplantation liver function deteriorated for a period, there was no HBV infection-related morbidity or mortality. Perioperative hepatitis B immunoglobulin prophylaxis can successfully prevent HBV naïve recipients from infection in some cases, but HBsAg-positive donors should only be considered in high risk situations.


Subject(s)
Heart Failure/surgery , Heart Transplantation , Hepatitis B/complications , Adult , Alanine Transaminase/blood , Antiviral Agents/therapeutic use , Biomarkers/blood , DNA, Viral/blood , Donor Selection , Female , Heart Failure/complications , Heart Transplantation/adverse effects , Hepatitis B/diagnosis , Hepatitis B/drug therapy , Hepatitis B/prevention & control , Hepatitis B Surface Antigens/blood , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Humans , Immunoglobulins/therapeutic use , Immunosuppressive Agents/therapeutic use , Lamivudine/therapeutic use , Male , Middle Aged , Retrospective Studies , Taiwan , Time Factors , Treatment Outcome , Viral Load , Virus Activation , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...